Beigene LtdNASDAQ:BGNE
- LAST PRICE146.7000
- TODAY'S CHANGE (%)4.0300 (2.8247%)
- Bid / Lots146.7200/ 4
- Ask / Lots147.3000/ 4
- Open / Previous Close144.3000 / 142.6700
- Day Range
- 52 Week Range
- Volume78,267
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BGNE |
|---|---|---|
| 09:32 ET | 3952 | 144.025 |
| 09:34 ET | 472 | 144.06 |
| 09:38 ET | 125 | 143.4 |
| 09:39 ET | 972 | 145.125 |
| 09:41 ET | 517 | 145.77 |
| 09:43 ET | 1212 | 147.03 |
| 09:45 ET | 1000 | 146.88 |
| 09:48 ET | 200 | 146.93 |
| 09:50 ET | 100 | 147.49 |
| 09:56 ET | 800 | 147.77 |
| 09:57 ET | 460 | 147.604 |
| 09:59 ET | 366 | 147.26 |
| 10:06 ET | 136 | 147.66 |
| 10:08 ET | 200 | 147.63 |
| 10:10 ET | 2800 | 147.49 |
| 10:12 ET | 2600 | 147.96 |
| 10:14 ET | 407 | 147.995 |
| 10:15 ET | 100 | 148.56 |
| 10:17 ET | 300 | 147.99 |
| 10:19 ET | 800 | 147.99 |
| 10:24 ET | 100 | 147.23 |
| 10:26 ET | 900 | 147.885 |
| 10:28 ET | 100 | 148.64 |
| 10:30 ET | 350 | 148.42 |
| 10:32 ET | 200 | 148.42 |
| 10:33 ET | 648 | 148.685 |
| 10:35 ET | 134 | 148.695 |
| 10:37 ET | 300 | 148.19 |
| 10:39 ET | 770 | 148.305 |
| 10:42 ET | 200 | 148.325 |
| 10:44 ET | 300 | 148.14 |
| 10:46 ET | 2435 | 148.32 |
| 10:50 ET | 450 | 148.2 |
| 11:00 ET | 607 | 147.55 |
| 11:02 ET | 671 | 148.19 |
| 11:04 ET | 1006 | 148.31 |
| 11:06 ET | 100 | 148.27 |
| 11:08 ET | 100 | 148.46 |
| 11:09 ET | 1408 | 148.29 |
| 11:11 ET | 300 | 148.14 |
| 11:15 ET | 1350 | 148.42 |
| 11:18 ET | 100 | 148.41 |
| 11:20 ET | 564 | 148.26 |
| 11:22 ET | 2965 | 148.94 |
| 11:24 ET | 281 | 148.54 |
| 11:26 ET | 300 | 148.425 |
| 11:27 ET | 1013 | 147.72 |
| 11:29 ET | 200 | 147.9 |
| 11:31 ET | 326 | 146.83 |
| 11:33 ET | 1656 | 147.195 |
| 11:38 ET | 700 | 147.205 |
| 11:40 ET | 1000 | 147.66 |
| 11:42 ET | 100 | 147.96 |
| 11:44 ET | 200 | 147.42 |
| 11:45 ET | 1255 | 147.71 |
| 11:49 ET | 100 | 147.97 |
| 11:54 ET | 100 | 147.81 |
| 11:58 ET | 435 | 147.694 |
| 12:00 ET | 1073 | 148.09 |
| 12:07 ET | 200 | 148.05 |
| 12:12 ET | 200 | 147.71 |
| 12:14 ET | 900 | 147.21 |
| 12:16 ET | 100 | 147.17 |
| 12:18 ET | 265 | 146.83 |
| 12:23 ET | 100 | 146.43 |
| 12:25 ET | 200 | 146.565 |
| 12:32 ET | 761 | 146.835 |
| 12:34 ET | 100 | 146.7 |
Jun 14, 2024
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA(R) plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024, from 6:00AM ET on Friday Jun 14, 2024 by Dow Jones
6:00AM ET on Friday Jun 14, 2024 by Dow Jones
Jun 13, 2024
Jun 4, 2024
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 6:01AM ET on Tuesday Jun 04, 2024 by Dow Jones
6:01AM ET on Tuesday Jun 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Beigene Ltd | 15.7B | -19.4x | --- |
Biomarin Pharmaceutical Inc | 15.6B | 78.0x | --- |
United Therapeutics Corp | 14.1B | 15.2x | +8.22% |
Neurocrine Biosciences Inc | 13.9B | 38.2x | +62.04% |
Medpace Holdings Inc | 12.8B | 41.7x | +35.10% |
Exact Sciences Corp | 7.8B | -31.9x | --- |
Company Information
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Contact Information
- Headquarters
- C/O Mourant Governance Services (Cayman) 94 Solaris Avenue, Camana BayGRAND CAYMAN, BEJ, Cayman Islands KY1-1108
- Phone
- 345-949-4123
- Fax
- ---
Executives
- Co-Founder, Executive Chairman of the Board, Chief Executive Officer
- John Oyler
- President, Chief Operating Officer, General Manager - China
- Xiaobin Wu
- Co-Founder, Non-Executive Director
- Xiaodong Wang
- Chief Financial Officer
- Julia Wang
- Senior Vice President, General Counsel
- Chan Lee
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.7B |
|---|---|
Revenue (TTM) | $2.8B |
Shares Outstanding | 105.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.59 |
EPS | $-7.57 |
Book Value | $36.95 |
P/E Ratio | -19.4x |
Price/Sales (TTM) | 5.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -26.60% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
